Momenta Phamaceuticals, Inc. (MNTA) Misses Q2 EPS by 2c; Affirms Outlook
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Financial Fact:
Total collaboration revenue: 29.14M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total collaboration revenue: 29.14M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q2 EPS of ($0.20), $0.02 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $18.99 million.
Momenta Phamaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Momenta Phamaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
- Live Ventures (LIVE) Reports Q3 Loss of $0.34
- MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
